{"protocolSection": {"identificationModule": {"nctId": "NCT00517634", "orgStudyIdInfo": {"id": "HZA109912"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects", "officialTitle": "A 12-week, Randomised, Double-blind, Placebo-controlled, Three-period, Cross-over Pilot Study Comparing the Effect of Salmeterol/Fluticasone Propionate, Fluticasone Propionate and Placebo on Perpheral Blood Eosinophils and Serum IL-5 in Response to Allergen Challenge in Asthma Subjects When Allergen Challenge is Administered at 1 Hour or 11-12 Hours Post-dose of the Dosing Interval"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-08"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-08-16", "studyFirstSubmitQcDate": "2007-08-16", "studyFirstPostDateStruct": {"date": "2007-08-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-07-23", "resultsFirstSubmitQcDate": "2009-07-23", "resultsFirstPostDateStruct": {"date": "2009-09-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-03", "lastUpdatePostDateStruct": {"date": "2016-12-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is influenced by the time of allergen challenge relative to the time of dosing.", "detailedDescription": "A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma", "allergen challenge", "IL-5", "eosinophils"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 23, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sequence 1: FP, SFC, Placebo", "type": "EXPERIMENTAL", "description": "Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period", "interventionNames": ["Drug: FP", "Drug: SFC", "Drug: Placebo"]}, {"label": "Sequence 2: Placebo, SFC, FP", "type": "EXPERIMENTAL", "description": "Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period", "interventionNames": ["Drug: FP", "Drug: SFC", "Drug: Placebo"]}, {"label": "Sequence 3: SFC, FP, Placebo", "type": "EXPERIMENTAL", "description": "Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period", "interventionNames": ["Drug: FP", "Drug: SFC", "Drug: Placebo"]}, {"label": "Sequence 4: SFC, Placebo, FP", "type": "EXPERIMENTAL", "description": "Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period", "interventionNames": ["Drug: FP", "Drug: SFC", "Drug: Placebo"]}, {"label": "Sequence 5: FP, Placebo, SFC", "type": "EXPERIMENTAL", "description": "Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period", "interventionNames": ["Drug: FP", "Drug: SFC", "Drug: Placebo"]}, {"label": "Sequence 6: Placebo, FP, SFC", "type": "EXPERIMENTAL", "description": "Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period", "interventionNames": ["Drug: FP", "Drug: SFC", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "FP", "description": "Fluticasone Propionate 100 mcg BD", "armGroupLabels": ["Sequence 1: FP, SFC, Placebo", "Sequence 2: Placebo, SFC, FP", "Sequence 3: SFC, FP, Placebo", "Sequence 4: SFC, Placebo, FP", "Sequence 5: FP, Placebo, SFC", "Sequence 6: Placebo, FP, SFC"]}, {"type": "DRUG", "name": "SFC", "description": "Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD", "armGroupLabels": ["Sequence 1: FP, SFC, Placebo", "Sequence 2: Placebo, SFC, FP", "Sequence 3: SFC, FP, Placebo", "Sequence 4: SFC, Placebo, FP", "Sequence 5: FP, Placebo, SFC", "Sequence 6: Placebo, FP, SFC"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching Placebo", "armGroupLabels": ["Sequence 1: FP, SFC, Placebo", "Sequence 2: Placebo, SFC, FP", "Sequence 3: SFC, FP, Placebo", "Sequence 4: SFC, Placebo, FP", "Sequence 5: FP, Placebo, SFC", "Sequence 6: Placebo, FP, SFC"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35", "description": "Number of peripheral blood eosinophils measured from blood draws", "timeFrame": "0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35"}], "secondaryOutcomes": [{"measure": "Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14", "description": "Number of peripheral blood eosinophils measured from blood draws", "timeFrame": "0-6 hours, post allergen challenge, 1 hour post treatment, Day 14"}, {"measure": "Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 35", "description": "Amount of serum interleukin (IL)-5 measured from blood draws", "timeFrame": "0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35"}, {"measure": "Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 14", "description": "Amount of serum IL-5 measured from blood draws", "timeFrame": "0-6 hours post allergen challenge, 1 hour after dosing, Day 14"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Informed consent.\n* Outpatient.\n* Male or non-pregnant/non-lactating female.\n* Aged 18-55.\n* Diagnosis of asthma.\n* Pre-bronchodilatory FEV1 \\> 75% predicted.\n* Using inhaled short-acting beta-2-agonists (SABA) with no inhaled corticosteroids.\n* Judged capable of withholding SABA for at least 6 hours prior to visits.\n* Reversibility of \\>12% and 200mL or PC20 of \\<8mg/mL.\n* Demonstration of atopy\n\nExclusion Criteria:\n\n* History of life-threatening asthma.\n* Use of proscribed asthma medications.\n* Use of anti-histamines or potent inhibitors of CYP3A4.\n* Respiratory tract infection.\n* Asthma exacerbation with 4 weeks of Visit 1.\n* Subjects with exercise induced asthma only.\n* Concurrent respiratory disease.\n* Other clinically significant, uncontrolled condition or disease.\n* Use of any investigational drug within 30 days.\n* Allergic to beta-2-agonists, inhaled corticosteroids or excipients.\n* Positive pregnancy test.\n* Using immunosuppressive medications.\n* Milk protein allergy.\n* Factors likely to interfere with attendance.\n* Current smokers or ex-smokers with a history of \\>10 pack years.\n* Affiliation wih Investigator site.\n* Medications that may affect the course of asthma or interact with sympathomimetic amines.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "HZA109912", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109912", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109912", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109912", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109912", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109912", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "HZA109912", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sequence 1: FP, SFC, Placebo", "description": "Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period"}, {"id": "FG001", "title": "Sequence 2: Placebo, SFC, FP", "description": "Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period"}, {"id": "FG002", "title": "Sequence 3: SFC, FP, Placebo", "description": "Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period"}, {"id": "FG003", "title": "Sequence 4: SFC, Placebo, FP", "description": "Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period"}, {"id": "FG004", "title": "Sequence 5: FP, Placebo, SFC", "description": "Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period"}, {"id": "FG005", "title": "Sequence 6: Placebo, FP, SFC", "description": "Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period"}], "periods": [{"title": "First Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Second Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Third Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Overall Study Population", "description": "Overall Study Population: participants in all three treatment periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "23"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36.6", "spread": "6.63"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "14"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35", "description": "Number of peripheral blood eosinophils measured from blood draws", "populationDescription": "Intent-to-Treat (ITT) Population: All participants receiving at least one dose of study medication who had at least one post-randomization efficacy assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Giga Units per Liter (GI/L)", "timeFrame": "0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo"}, {"id": "OG001", "title": "FP 100 mcg BID", "description": "Fluticasone Propionate (FP) 100 mcg BID"}, {"id": "OG002", "title": "SFC 50/100 mcg BID", "description": "Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.050", "lowerLimit": "-0.072", "upperLimit": "-0.029"}, {"groupId": "OG001", "value": "-0.040", "lowerLimit": "-0.061", "upperLimit": "-0.019"}, {"groupId": "OG002", "value": "-0.023", "lowerLimit": "-0.044", "upperLimit": "-0.001"}]}]}]}, {"type": "SECONDARY", "title": "Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14", "description": "Number of peripheral blood eosinophils measured from blood draws", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Giga Units per Liter (GI/L)", "timeFrame": "0-6 hours, post allergen challenge, 1 hour post treatment, Day 14", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo"}, {"id": "OG001", "title": "FP 100 mcg BID", "description": "Fluticasone Propionate (FP) 100 mcg BID"}, {"id": "OG002", "title": "SFC 50/100 mcg BID", "description": "Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.023", "lowerLimit": "-0.039", "upperLimit": "-0.006"}, {"groupId": "OG001", "value": "-0.022", "lowerLimit": "-0.038", "upperLimit": "-0.007"}, {"groupId": "OG002", "value": "-0.013", "lowerLimit": "-0.029", "upperLimit": "-0.004"}]}]}]}, {"type": "SECONDARY", "title": "Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 35", "description": "Amount of serum interleukin (IL)-5 measured from blood draws", "reportingStatus": "NOT_POSTED", "timeFrame": "0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 14", "description": "Amount of serum IL-5 measured from blood draws", "reportingStatus": "NOT_POSTED", "timeFrame": "0-6 hours post allergen challenge, 1 hour after dosing, Day 14", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 22, "otherNumAffected": 14, "otherNumAtRisk": 22}, {"id": "EG001", "title": "FP 100 mcg BID", "description": "Fluticasone Propionate 100 mcg BID", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 16, "otherNumAtRisk": 23}, {"id": "EG002", "title": "SFC 50/100 BID", "description": "Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID", "seriousNumAffected": 1, "seriousNumAtRisk": 22, "otherNumAffected": 10, "otherNumAtRisk": 22}], "seriousEvents": [{"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 22}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 22}]}, {"term": "Pharyngolarngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 22}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Dry Throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Rhinorrhea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Eye pruritus", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Multiple allergies", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Nerve compression", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Periorbital haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 22}]}, {"term": "Pharyngeal disorder", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Sinus congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Sneezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Tooth abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "House dust allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Muscle strain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Post procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}, {"term": "Tooth extraction", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 22}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M250", "name": "Fluticasone", "relevance": "LOW"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}